757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab by Michael Chisamore, Jeffrey Yachnin, Ana Carneiro, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Lars Ny, Zsuzsanna Pápai, Kristoffer Staahl Rohrberg, Kirstie Cleary, Jan Anders Nilsson, Sean Lim, Johan E Wallin, Istvan Lang, Harriet Walter, Rikke H Lovendahl Eefsen, Edvard Abel, Robert Oldham, Susanne Gertsson